Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
Thomas E. Shenk to Retire From Merck's Board of Directors
Merck Press Release (02/08/12)
Merck has announced that Thomas E. Shenk has decided to retire from its board of directors, effective immediately. Shenk is leaving the board to focus on the new company he is forming to commercialize discoveries made in his Princeton University laboratory in the area of antiviral therapeutics. Shenk has been Elkins Professor in the Department of Molecular Biology at Princeton University since 1984. He joined Merck's board in 2001.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
